ArticleDNA and cell biology2002
The mouse alpha-fetoprotein promoter is repressed in HepG2 hepatoma cells by hepatocyte nuclear factor-3 (FOXA).
Article in DNA and cell biology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Generation of a tumor- and tissue-specific episomal non-viral vector system.BMC biotechnology · 2013Article
- Functional promoter haplotypes of interleukin-18 condition susceptibility to severe malarial anemia and childhood mortality.Infection and immunity · 2011Article
- Zhx2 and Zbtb20: novel regulators of postnatal alpha-fetoprotein repression and their potential role in gene reactivation during liver cancer.Seminars in cancer biology · 2011Review
- Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM.Molecular and cellular biology · 2010Article
- PDGF-A promoter and enhancer elements provide efficient and selective antineoplastic gene therapy in multiple cancer types.Cancer gene therapy · 2009Article
- ZHX2 is a repressor of alpha-fetoprotein expression in human hepatoma cell lines.Journal of cellular and molecular medicine · 2008Article
- Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance.The Journal of infectious diseases · 2008Article
- Alpha-fetoprotein: from a diagnostic biomarker to a key role in female fertility.Biomarker insights · 2007Article
- Alternative promoters determine tissue-specific expression profiles of the human microsomal epoxide hydrolase gene (EPHX1).Molecular pharmacology · 2005Article
- FoxA proteins regulate H19 endoderm enhancer E1 and exhibit developmental changes in enhancer binding in vivo.Molecular and cellular biology · 2004Article
- A proximal tissue-specific module and a distal negative regulatory module control apolipoprotein(a) gene transcription.The Biochemical journal · 2004Article
- Alpha-fetoprotein: A Multifaceted Player in Cancer Biology.Euroasian journal of hepato-gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The mouse alpha-fetoprotein gene is expressed at high levels in the fetal liver and is transcriptionally silenced at birth. The repression is governed, at least in part, by the 250 base pair (bp) AFP promoter. We show here that the AFP promoter is dramatically repressed by HNF3 in HepG2 hepatoma cells. This repression is governed by the region between -205 and -150. Furthermore, this fragment can confer HNF3-mediated repression on a heterologous promoter. The repression is abolished by a mutation that is centered at -165. EMSA analyses using in vivo and in vitro synthesized proteins indicate that HNF3 proteins do not bind DNA from the -205 to -150 region. We propose that HNF3 represses AFP promoter activity through indirect mechanisms that modulate the binding or activity of a liver-enriched factor that interacts with the -165 region of the AFP promoter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.